Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. is dated May 14, 2019. DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for food allergies and other immune diseases. The company is headquartered in Montrouge, France, with additional offices in New York, NY.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate governance update regarding executive leadership.
Material Changes
- Executive Departure: David Schilansky, Deputy Chief Executive Officer and Principal Financial Officer, announced his departure to pursue other opportunities.
- Transition Period: Mr. Schilansky will remain with the company through August 2019 to ensure a smooth transition.
- Role Restructuring: The company will not fill the Deputy CEO role following Mr. Schilansky's departure.
- Search for Replacement: A search for a new Chief Financial Officer is currently underway.
Outlook, Risks, and Management Commentary
CEO Daniel Tassé acknowledged Mr. Schilansky's contributions, particularly during the company's transition from a French-based R&D entity to a potential global commercial-stage organization. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard operational risks associated with executive turnover.
Key Facts for Investor Verification
- Confirm the timeline for the appointment of the new Chief Financial Officer.
- Verify the status of ongoing clinical trials for Viaskin Peanut and Viaskin Milk to ensure no disruption from the leadership change.
- Monitor future filings for the formal announcement of the new CFO and any changes to the company's financial strategy.
- Check the company's cash runway in subsequent quarterly reports, as this filing does not disclose current liquidity levels.